AstraZeneca makes a deal to buy another biotech company, this one with a price tag that could reach $1 billion.

The deal includes the Belgian biotech’s in-vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...

From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 million upfront, building out another cancer-targeting approach.

(Bloomberg) — AstraZeneca Plc (AZN) will invest $2.5 billion in a new research center in Beijing, in a major show of commitment to China just months after the company’s top executive there was ...

AstraZeneca has a large presence in emerging markets and should benefit from these markets' fast growth prospects. The company's strong entrenchment in respiratory disease could cause challenges ...

AstraZeneca, headquartered in Cambridge, could pay up to $1 billion on a cash and debt-free basis for Belgian company ...

Brief host Brad Smith tracks several of this morning's trending stocks and market stories, including Micron Technology's (MU) ...